Anthony Smithyman
Chief Executive Officer at Special Phage Holdings Pty Ltd.
Profile
Anthony Smithyman is the founder of Special Phage Holdings Pty Ltd.
which was founded in 2004.
He held the title of Managing Director at the company.
Currently, he is the Managing Director at Cellabs Pty Ltd.
Dr. Smithyman was a Director at AmpliPhi Biosciences Corp.
from 2012 to 2015.
Dr. Smithyman holds a doctorate degree from the University of Glasgow and an undergraduate degree from the University of St. Andrews.
Anthony Smithyman active positions
| Companies | Position | Start |
|---|---|---|
Special Phage Holdings Pty Ltd.
 Special Phage Holdings Pty Ltd. Medical SpecialtiesHealth Technology Part of Innoviva, Inc., Special Phage Holdings Pty Ltd. operates as a holding Australian company with interests in phage therapy. The company is based in Neutral Bay, Australia. The company was founded by Anthony Smithyman. Anthony Smithyman has been the CEO since incorporation. Special Phage Holdings was acquired by AmpliPhi Australia Pty Ltd. on November 13, 2012 for $6.77 million. | Chief Executive Officer | 2014-01-22 |
Cellabs Pty Ltd.
 Cellabs Pty Ltd. Medical/Nursing ServicesHealth Services Cellabs Pty Ltd. is a boutique diagnostics company based in Sydney that specializes in designing, developing, and manufacturing immunodiagnostic kits for tropical and infectious diseases. The Australian company's focus is on providing accurate and reliable diagnostic solutions to healthcare professionals and patients. The CEO of the private company is Anthony Smithyman. | Chief Executive Officer | - |
Former positions of Anthony Smithyman
| Companies | Position | End |
|---|---|---|
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Director/Board Member | 2015-04-15 |
Training of Anthony Smithyman
| University of Glasgow | Doctorate Degree |
| University of St. Andrews | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Cellabs Pty Ltd.
Cellabs Pty Ltd. Medical/Nursing ServicesHealth Services Cellabs Pty Ltd. is a boutique diagnostics company based in Sydney that specializes in designing, developing, and manufacturing immunodiagnostic kits for tropical and infectious diseases. The Australian company's focus is on providing accurate and reliable diagnostic solutions to healthcare professionals and patients. The CEO of the private company is Anthony Smithyman. | Health Services |
Special Phage Holdings Pty Ltd.
Special Phage Holdings Pty Ltd. Medical SpecialtiesHealth Technology Part of Innoviva, Inc., Special Phage Holdings Pty Ltd. operates as a holding Australian company with interests in phage therapy. The company is based in Neutral Bay, Australia. The company was founded by Anthony Smithyman. Anthony Smithyman has been the CEO since incorporation. Special Phage Holdings was acquired by AmpliPhi Australia Pty Ltd. on November 13, 2012 for $6.77 million. | Health Technology |
- Stock Market
- Insiders
- Anthony Smithyman
